Index

Note: Page numbers in italic refer to Figures; those in bold to Tables.

activities of daily living (ADLs), 105, 125–6
AD8 dementia screening questionnaire, 3, 87
adrenergic receptor antagonists, 115, 115
advance care planning (ACP), 127
agitation and aggression
  mild
    antidepressants, 113–14
    cholinesterase inhibitors and memantine, 112–13
  moderate to severe
    adrenergic receptor antagonists, 115, 115
    anticonvulsants, 116
    antipsychotics, 114–15, 115
    benzodiazepines, 116, 116
pharmacological treatment, 112, 112
Alzheimer’s disease, 3, 8
Alzheimer’s Disease Antiinflammatory Prevention Trial (ADAPT), 166
Alzheimer’s disease assessment scale-cognitive subscale (ADAS-Cog), 154
Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC), 159
Alzheimer’s disease-related quality of life (ADRQL), 156
anticholinergic agents, 103
anticonvulsants, 116
antidementia medications, 101
antidepressants
  dementia-related agitation, 113, 113, 114
  MCI, 93
  neurological care, outpatient, 103
antipsychotics
  atypical, 114, 115
  black box warning, FDA, 114
description, 114
dose reduction, 114–15
side-effects, 114
apathy vs. depression, 71
autoimmune diseases, RPD
  autoantibody testing, 21, 22, 23
  awareness, 18
cancer screening, 25
  cerebrospinal fluid measures, 25
diagnosis, 23
eletroencephalogram (EEG), 25
etiology and pathogenesis, 19
LE, 18–19
MMSE, 19
neural autoantibodies, 19, 20, 21, 22
neuroimaging, 23, 24
NMDA receptor, 22–3
testing, 23
treatment
  algorithm, 25, 26
  cancer, 25
  chronic therapy, 28–9
  common therapies, 25, 27
  immunotherapy, 25, 26, 28
  VGKC antibodies, 19–20, 22
young-onset dementia, 18
Beers Criteria for Potentially Inappropriate Medication Use in Older Adults, 121
behavioral-variant frontotemporal dementia (bvFTD), 10, 119
benzodiazepines, 116, 116
brain sagging, 49–50
brain therapy, 108
burdensome transition, 122
bvFTD see behavioral-variant frontotemporal dementia (bvFTD)
caring for caregivers
  ABCD-RIK, 147–8
  advocacy organizations, 148
  stress and burnout identification, 147
  support groups and educational interventions, 148
CBS see Cornell-Brown Scale for QoL in Dementia (CBS)
CDR see Clinical Dementia Rating Scale (CDR)
cholinesterase inhibitors (CIs)
  donepezil, 101
galantamine, 101
  and memantine, 112–13
  rivastigmine, 101
Clinical Dementia Rating Scale (CDR), 146, 159
Controlled Oral Word Association Test (COWAT), 80

© 2014 John Wiley & Sons, Ltd. Published 2014 by John Wiley & Sons, Ltd.
Cornell-Brown Scale for QoL in Dementia (CBS), 156
Creutzfeldt–Jakob disease, 17
decision making, cognitive impairment assessment
   ability to appreciate, 139
   expression of choice, 139
   reasoning ability, 139
   standardized tools, 139
   understanding ability, 139
capacity vs. competence, 138
impaired decision-making capacity, 140
informed consent, 138
substituted interests model
description, 142
   quality of life and dignity, patient, 142–3
   shared decision making, 142
   values and beliefs, patient, 142
surrogate decision making, 140–141
DECO see Deterioration Cognitive Observation Scale (DECO)
dementia
Alzheimer’s disease, 3, 8
   assessment
      depression, 3
      familial dementia, 4–5
      guidelines, 2
      memory impairment, 3, 4
      Neuropsychiatric Inventory (NPI), 4
      standardized questionnaires, 3, 4
      vascular risk factors, 4
biomarkers, 11
blood and spinal fluid, 6–7
burdensome transition, 122
cognitive evaluation, 5
definition, 1, 3
depression, 73–5
description, 121
differential diagnosis, 7, 8, 9
epidemiology, 3
frontotemporal, 10
imaging, 7, 11–12
Lewy body dementia, 10
neurological care see neurological care, outpatient
neurological examination, 5–6
palliative care see palliative care
physical examination, 5
problems, current classifications, 10–11
vascular see vascular dementia
depression see also problem behaviors, dementia
   vs. apathy, 71
description, 67
elderly, 71–3
geriatric see geriatric depression
   management, dementia patients
   antidepressant medications, 73
   ECT, 74–5
   pharmacological management, 73, 74
   SSRIs, 73
   tricyclic antidepressants, 74
   risk factor, Alzheimer’s dementia, 164
Deterioration Cognitive Observation Scale (DECO), 3
driving restrictions, 145–6
The Dubois criteria, prodromal AD, 87
electroconvulsive therapy (ECT), 74–5
endoscopic third ventriculostomy (ETV), 64
ethical, legal and social issues
   clinicians
      advance directives, 144–5
      caring for caregivers, 147–8
      driving, 145–6
      elder abuse, 146–7
      participation, research, 143–4
      voting, 146
decision making see decision making, cognitive impairment
providing care
   autonomy, patient, 137
   caregivers, 137–8
   cognitive decline, 137
   social and cultural reflections, 148
ETV see endoscopic third ventriculostomy (ETV)
familial disorders, YOD, 37, 38–45
FAQ see functional assessment questionnaire (FAQ)
frontotemporal dementia
   bvFTD, 10
   differential diagnosis, 9
   progranulin levels, 11
frontotemporal dementia (FTD) syndrome, 48
functional assessment questionnaire (FAQ), 155
gait and balance, NPH, 57–8
GDS see geriatric depression scale (GDS)
GEM study see Ginkgo Evaluation of Memory (GEM) study
geriatric depression
   and Alzheimer’s disease, 68
   autopsy studies, 69
   biopsychosocial factors, 70–71
   and dementia, 68, 69
   DSM-IV-TR diagnostic criteria, 67, 68
   hippocampal atrophy, 69
   prevalence, 68
   pseudodementia, 68–9
   vascular depression hypothesis, 70
geriatric depression scale (GDS), 157
Ginkgo Evaluation of Memory (GEM) study, 166

hallucinations and delusions
AD, 116, 117
antipsychotic treatment, 116–17
clozapine and quetiapine, 117
DLB and PDD patients, 116, 117

Health Insurance Portability and Accountability Act (HIPPA), 99
heredodegenerative disorders, 18
hospitalization, 107
hypercholesterolemia, 164–5
hyponatremia, 48

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE), 3
instrumental activities of daily living (IADLs), 4, 104, 125

The Katz Index of Independence, ADL, 155
Lawton Instrumental Activities of Daily Living Scale, 155
Lewy body dementia, 10
“Life’s Simple 7”, 168
long-standing overt ventriculomegaly in adults (LOVA), 56

macrocytic and microcytic anemia, 48
major depressive disorder
DSM-IV-TR diagnostic criteria, 67, 68
lack of interest, pleasurable activities, 71
prevalence, 68
sensitivity and specificity, 72

symptoms, 71
MCI see mild cognitive impairment (MCI)
magazines, neurological care
administration, 107
alternative medicine, 102–3
anticholinergic agents, 103
antidementia medications, 101
antidepressants, 103
benzodiazepines, 103
CIs, 101
combination therapy, 102
list and supervision, 100
managing expectations, 102
NMDA antagonist, 101–2
off-label prescribing, 102
prescribing considerations, 101
sleep aids, 103
mild cognitive impairment (MCI)
amnestic, 78
biomarkers
amyloid PET, 85
CSE, 82

FDG-PET and SPECT scans, 86
genetic markers, 86
MRI, 82–5
neuroimaging, 82
definition, 77–8
differential diagnosis, etiological subtypes, 88, 89, 90
ethical considerations, 91–2
etiological subtype diagnosis
accuracy, 86
cognitive impairment, 86
MCI-AD, 87
VaMCI, 88
neuropsychological assessment

cognitive screening tests, 80
COWAT, 80
and educational levels, 81
recommended measures, 81
pathophysiology, 79–80
Petersen's criteria, 77–8
predictors, rate of progression, 92
prevention
avoidance, prescription medications, 94
lifestyle changes, 94
medical risk factors management, 94
supplements and prescription medications, 94
psychiatric aspects, 91
subtypes, 78, 79
treatment, 93
Mini-Cog test, 105
mini-mental state examination (MMSE)
description, 153
education-adjusted norms, 153
Montreal Cognitive Assessment (MOCA), 105
montreal cognitive assessment (MoCA), 153–4
mortality risk index (MRI), 134, 134

The National Center on Elder Abuse (NCEA), 146–7
neurological care, outpatient
ADLs
behavior and mood, 105
cognition, 105–6
delay nursing home placement, 106
anesthesia and surgery, 104
caregiving, 108–9
dementia stages, 104
diagnosis, 99–100
family conferences, 100
follow-up assessment, 105
genetics and prevention, 107–8
hospitalization, 107
medications see medications, neurological care
neuroimaging and laboratory testing, 107
neurologist role, 98
partnering, 98–9
neurological care, outpatient (cont’d) planning, 106 
prognosis, 104–5 
research, 108 
weapons and hunting, 107 
neuropsychiatric inventory (NPI), 157 
neuropsychiatric symptoms assessment, 156–7 
description, 156 
GDS, 157 
inpatient psychiatric hospitalization, 157 
NPI, 157 
neuropsychological testing, 154 
NIA-ADC Uniform Data Set, 152 
normal pressure hydrocephalus (NPH) classification, 55–6 
demographics, 55 
differential diagnosis, 58, 61 
idiopathic, 58, 59–61 
neuroimaging, 61–3, 62 
pathophysiology 
CSF pulse pressures, 56–7 
head circumference, 56 
LOVA, 56 
prognosis, 63 
symptoms cognition, 58 
gait and balance, 57–8 
psychiatric, 58 
urination control, 58 
treatment complications, 64 
LOVA and AS, 64 
low-dose acetazolamide, 64 
non-surgical, 64 
programmable valves, 64 
shunt valves, 63–4 
normocytic anemia, 48 
NPH see normal pressure hydrocephalus (NPH) outcomes assessment, care ADAS-Cog, 154 
caregiver burden, 157–8 
cognition, 153 
functional abilities, 155 
global assessment, 158–9 
hospitalizations, nursing home placement and mortality, 159–60 
instruments, 152 
MMSE, 153 
MoCA, 153–4 
neuropsychiatric symptoms, 156–7 
neuropsychological testing, 154 
pay for performance and quality measures, 152, 160–161 
quality of life, 155–6 
SLUMS, 154 
palliative care ADL, 125–6 
alleviation, suffering 
non-steroidal antinflammatory medications, 125 
pain and physical distress, 124, 125 
Pro re nata (prn) medications, 125 
quality of life, 125 
self-reporting, 124–5 
counseling and anticipatory guidance, 127–8 
decision making and ACP, 127 
disease trajectory, 123–4 
and families 
decision making, 126, 127 
elderly person, 126 
supportive counseling, 126 
life completion and closure, 128 
predictable patient and family needs 
care planning, 122 
end of life, 123 
hospice programs, 122 
supportive counseling, 122 
training, caregivers, 122 
prognostication and hospice care, 133–5 
"Watch Over Me" see "Watch Over Me" partnering, dementia care, 98–9 
The 1990 Patient Self Determination Act, 144 
Physician Quality Reporting Initiative (PQRI), 160 
Physician Quality Reporting System (PQRS), 160 
Physician’s Order for Life Sustaining Treatment (POLST), 127 
primary prevention AD and vascular risk, 164 
cognitive benefits, controlling depression, 168 
controlled clinical trials, 165–6, 167 
recommendations risk factors, Alzheimer’s dementia 
B vitamin-related hyperhomocysteinemia, 165 
cognitive inactivity, 164 
depression, 164 
diabetes mellitus, 164 
estrogen, 165 
hypercholesterolemia, 164–5 
hypertension, 164 
low antioxidant intake, 165 
low omega 3 fatty acid intake, 165 
medications, 165 
obesity, 164 
physical inactivity, 164 
smoking, 164 
trace metals, 165 
problem behaviors, dementia
agitation and aggression see agitation and aggression
apathy, 118–19
bvFTD see behavioral-variant frontotemporal dementia
(bvFTD)
depression
description, 117
diagnosis, 118
DSM-IV TR criteria, 118
hallucinations and delusions, 116–17
psychotropic medications, 111
sleep disturbance, 117, 117
treatment
assessment, 111
geriatric populations, 112
non-pharmacological approaches, 111, 112
pseudodementia, 68–9
psychosis see hallucinations and delusions
quality of life (QoL), 155–6
quality of life-Alzheimer’s disease (QoL-AD), 156
rapidly progressive dementia (RPD)
autoimmune causes see autoimmune
diseases, RPD
biopsy, 33
definition, 15
diagnostic algorithm, 16, 17
epidemiology, 15, 17
heredodegenerative disorders, 18
infectious causes
bacterial, 30
fungal, parasitic, and mycobacterial, 30
viral, 29–30
leukodystrophies, 32, 33
metabolic causes, 31, 33
mitochondrial disorders, 33
neoplastic causes, 30–31
neurodegenerative dementia, 17–18
psychiatric causes, 31
spongiform disorders, 17
toxic causes, 31
vascular causes, 29
Revised Memory and Behavior Problem Checklist
(RMBPC), 158
RPD see rapidly progressive dementia (RPD)
SIADH see syndrome of inappropriate antidiuretic hormone
secretion (SIADH)
sleep aids, 103
sleep disturbance, 117, 117
spongiform disorders, 17
St Louis University Mental Status Examination
(SLUMS), 154
substituted judgment standard, 140–141
syndrome of inappropriate antidiuretic hormone
secretion (SIADH), 20
The National Hospice and Palliative Care
Organization (NHPCO) hospice eligibility
criteria, 133–4
thrombocytosis, 48
"two hit" hypothesis, NPH, 56
urination control, NPH, 58
vascular dementia, 8, 10
vascular MCI (VaMCI), 88, 93
"Watch Over Me"
anonymity, 130
artificial hydration and nutrition, 132–3
caregivers, 129
communication, patients and families, 129
conversational guiding principles, 133
create the space, 129
death, loved one, 131–2
description, 128
goal-based vs. problem-based approach to care, 132
hope, identification, 130–131
preparation, 129
relief in grief feelings, 131
setting agenda, 129
tailoring, 131
understanding of illness determination, 130
white matter disease, 49
YOD see young onset dementia (YOD)
young onset dementia (YOD)
diagnosis
familial disorders, 37, 38–45
recommendations, staged approach, 36
diagnostic testing (round 1)
brain sagging, 49–50
cognitive and behavioral symptoms, 48
diffusion-weighted imaging, 49
etiologies, 37, 46–7
frontotemporal dementia (FTD) syndrome, 48
hyponatremia, 48
macrocytic and microcytic anemia, 48
magnetic resonance imaging (MRI) study, 49
neuroimaging and laboratory studies, 37
normocytic anemia, 48
thrombocytosis, 48
white matter disease, 49
diagnostic testing (round 2)
autoimmune and collagen vascular diseases, 50
cerebrospinal fluid examination, 50–51
EEG, 50
young onset dementia (YOD) (cont’d)
- neuropsychological assessment, 50
- paraneoplastic antibody, 51
- PET scan, 51
- diagnostic testing (round 2.5), 51
- FDG-PET, 51–2
- 24-h urinary collection, 52
- hypometabolism, 52
- mitochondrial cytopathy, 52

- serum and CSF lactate and pyruvate, 52
- slit-limp examination, 52
- diagnostic testing (round 4)
- antemortem examination, cerebral tissue, 53
- biopsy, 53
- genetic testing, 52
- epidemiology, 35
- unsuccessful diagnosis, 53–4

- Zarit Burden Interview, 158